Compare · IDXG vs SYK
IDXG vs SYK
Side-by-side comparison of Interpace Biosciences, Inc. (IDXG) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXG and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK carries a market cap of $103.57B.
- Both names hit the wire about 9 times in the past 4 weeks.
- SYK has more recent analyst coverage (25 ratings vs 1 for IDXG).
- Company
- Interpace Biosciences, Inc.
- Stryker Corporation
- Price
- -
- $270.00-2.00%
- Market cap
- -
- $103.57B
- 1M return
- -
- -22.45%
- 1Y return
- -
- -30.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 9
- 9
- Recent ratings
- 1
- 25
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest IDXG
- Interpace Biosciences, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: Interpace Biosciences, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Interpace Biosciences, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEO, President & Chairman Burnell Thomas W. converted options into 1,966,763 shares and covered exercise/tax liability with 581,718 shares, increasing direct ownership by 1,954% to 1,455,927 units (SEC Form 4) to cover taxes
- SEC Form 4 filed by Director Aggarwal Vijay
- SEC Form 4 filed by Director Keegan Joseph D
- SEC Form 4 filed by Director Rocca Fortunato R.
- SEC Form 4 filed by Director Sullivan Stephen J
- CFO & COO Mccarthy Christopher converted options into 277,009 shares, increasing direct ownership by 592% to 323,800 units (SEC Form 4)
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SYK
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)
- Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
- Director Brainerd Mary K bought $26,736 worth of shares (131 units at $204.09) (SEC Form 4)
- Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
- Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
- Stryker to participate in the 2026 Wells Fargo Healthcare Conference
- Group President Crotty Dylan Bram sold $144,915 worth of shares (441 units at $328.61) (SEC Form 4)
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research